Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis.
Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis.
复制标题
DOI：
10.1136/bmj-2022-070230
复制
发表时间：
2022-04-27
影响因子：
105.7
通讯作者：
Calvert, Melanie J.
中科院分区：
文献类型：
--
作者：
Hughes, Sarah E.;Haroon, Shamil;Subramanian, Anuradhaa;McMullan, Christel;Aiyegbusi, Olalekan L.;Turner, Grace M.;Jackson, Louise;Davies, Elin Haf;Frost, Chris;McNamara, Gary;Price, Gary;Matthews, Karen;Camaradou, Jennifer;Ormerod, Jane;Walker, Anita;Calvert, Melanie J.
为了描述一种新的患者报告的长时间症状负担的结果测量方法的开发和验证，长时间症状负担问卷(SBQ-LC)。多阶段、前瞻性混合方法研究。联合王国远程数据收集和社交媒体渠道，2021年4月14日至8月1日。13名成人(年龄18岁，≥)，自报长期卧床不起，10名临床医生评估内容的有效性。对274例成人长冠状野问卷进行了测试。发表了系统的评论，了解了SBQ-LC的概念框架和初始项目库的发展。对认知情况汇报访谈和在线临床医生调查的记录进行主题分析，确定了内容有效性。与患者和公众参与小组就非住院个人长期COVID的治疗进行了协商一致的讨论：从症状、患者报告的结果和免疫学到靶向治疗(TLC研究)证实了表面有效性。现场测试数据的RASCH分析指导了项目和量表的改进，并提供了SBQ-LC测量特性的初步证据。SBQ-LC(1.0版)是一种测量患者报告结果的模块化工具，由17个独立的量表组成，具有良好的心理测量学特性。受访者使用二分反应或4分评定量表对过去七天的症状负担进行评分。每个量表提供不同症状领域的覆盖范围，并返回可转换为线性(0-100)分数的原始总分。得分越高，症状负担越大。经过评定量表的细化和条目缩减，所有量表都满足Rasch模型对单维度(残差主成分分析：第一残差对比值和2.00个特征值单位)和项目拟合度(装备均方根值在0.5-1.5个对数内)的要求。使用可接受的类别匹配统计数据(装备均方根值和2.0logits)对评级量表类别进行排序。有14个项目对有本地相关性(剩余相关值0.4)。在17个量表中，人的信度在0.34到0.87之间，人与人之间的距离在0.71到2.56之间，条目距离在1.34到13.86之间，内部一致性信度(Cronbach‘sα)在0.56到0.91之间。SBQ-LC(1.0版)是一种使用现代心理测量方法开发的综合性患者报告结果工具。它测量了长期卧床的症状，对有这种情况的人很重要，可以用来评估干预措施的影响，并为临床管理提供最佳实践。
To describe the development and validation of a novel patient reported outcome measure for symptom burden from long covid, the symptom burden questionnaire for long covid (SBQ-LC). Multiphase, prospective mixed methods study. Remote data collection and social media channels in the United Kingdom, 14 April to 1 August 2021. 13 adults (aged ≥18 years) with self-reported long covid and 10 clinicians evaluated content validity. 274 adults with long covid field tested the draft questionnaire. Published systematic reviews informed development of SBQ-LC’s conceptual framework and initial item pool. Thematic analysis of transcripts from cognitive debriefing interviews and online clinician surveys established content validity. Consensus discussions with the patient and public involvement group of the Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient reported outcomes and immunology to targeted therapies (TLC Study) confirmed face validity. Rasch analysis of field test data guided item and scale refinement and provided initial evidence of the SBQ-LC’s measurement properties. SBQ-LC (version 1.0) is a modular instrument measuring patient reported outcomes and is composed of 17 independent scales with promising psychometric properties. Respondents rate their symptom burden during the past seven days using a dichotomous response or 4 point rating scale. Each scale provides coverage of a different symptom domain and returns a summed raw score that can be transformed to a linear (0-100) score. Higher scores represent higher symptom burden. After rating scale refinement and item reduction, all scales satisfied the Rasch model requirements for unidimensionality (principal component analysis of residuals: first residual contrast values <2.00 eigenvalue units) and item fit (outfit mean square values within 0.5 -1.5 logits). Rating scale categories were ordered with acceptable category fit statistics (outfit mean square values <2.0 logits). 14 item pairs had evidence of local dependency (residual correlation values >0.4). Across the 17 scales, person reliability ranged from 0.34 to 0.87, person separation ranged from 0.71 to 2.56, item separation ranged from 1.34 to 13.86, and internal consistency reliability (Cronbach’s alpha) ranged from 0.56 to 0.91. SBQ-LC (version 1.0) is a comprehensive patient reported outcome instrument developed using modern psychometric methods. It measures symptoms of long covid important to people with lived experience of the condition and may be used to evaluate the impact of interventions and inform best practice in clinical management.
登录
查看更多内容
DOI：
10.1016/s2213-2600(21)00383-0
发表时间：
2021-11
期刊：
The Lancet. Respiratory medicine
影响因子：
--
作者：
Evans RA;McAuley H;Harrison EM;Shikotra A;Singapuri A;Sereno M;Elneima O;Docherty AB;Lone NI;Leavy OC;Daines L;Baillie JK;Brown JS;Chalder T;De Soyza A;Diar Bakerly N;Easom N;Geddes JR;Greening NJ;Hart N;Heaney LG;Heller S;Howard L;Hurst JR;Jacob J;Jenkins RG;Jolley C;Kerr S;Kon OM;Lewis K;Lord JM;McCann GP;Neubauer S;Openshaw PJM;Parekh D;Pfeffer P;Rahman NM;Raman B;Richardson M;Rowland M;Semple MG;Shah AM;Singh SJ;Sheikh A;Thomas D;Toshner M;Chalmers JD;Ho LP;Horsley A;Marks M;Poinasamy K;Wain LV;Brightling CE;PHOSP-COVID Collaborative Group
通讯作者：
PHOSP-COVID Collaborative Group
影响因子：
8.8
作者：
de Haes JC;van Knippenberg FC;Neijt JP
通讯作者：
Neijt JP
DOI：
10.1016/j.bjps.2019.05.039
发表时间：
2019-11-01
影响因子：
2.7
作者：
Harrison, Conrad J.;Geerards, Daan;Sidey-Gibbons, Chris J.
通讯作者：
Sidey-Gibbons, Chris J.
影响因子：
9.9
作者：
Flesch, Rudolf
通讯作者：
Flesch, Rudolf
影响因子：
3.5
作者：
Herdman, M.;Gudex, C.;Lloyd, A.;Janssen, M. F.;Kind, P.;Parkin, D.;Bonsel, G.;Badia, X.
通讯作者：
Badia, X.